Co-Authors
This is a "connection" page, showing publications co-authored by JEFFREY L JORGENSEN and SANAM LOGHAVI.
Connection Strength
1.866
-
B-acute lymphoblastic leukemia/lymphoblastic lymphoma. Am J Clin Pathol. 2015 Sep; 144(3):393-410.
Score: 0.531
-
Hematogones with light chain restriction: A potential diagnostic pitfall when using flow cytometry analysis to assess bone marrow specimens. Leuk Res. 2021 12; 111:106704.
Score: 0.202
-
Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1-mutated acute myeloid leukaemia. Br J Haematol. 2021 03; 192(6):1054-1063.
Score: 0.194
-
Immunophenotypic and diagnostic characterization of angioimmunoblastic T-cell lymphoma by advanced flow cytometric technology. Leuk Lymphoma. 2016 12; 57(12):2804-2812.
Score: 0.139
-
Long-term results of the sequential combination of cladribine and rituximab in Hairy cell leukemia. Leuk Lymphoma. 2024 Sep; 65(9):1325-1334.
Score: 0.061
-
Validation of a 12-color flow cytometry assay for acute myeloid leukemia minimal/measurable residual disease detection. Cytometry B Clin Cytom. 2023 Sep; 104(5):356-366.
Score: 0.058
-
Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity. Blood Adv. 2023 07 11; 7(13):3284-3296.
Score: 0.057
-
Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia. J Hematol Oncol. 2023 05 02; 16(1):44.
Score: 0.056
-
Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results. Am J Hematol. 2023 03; 98(3):493-501.
Score: 0.055
-
Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease?(MRD) recurrence following MRD-negative remission. Am J Hematol. 2022 11; 97(11):E408-E411.
Score: 0.054
-
Blastic plasmacytoid dendritic cell neoplasm with history of myeloma and concomitant acute undifferentiated leukemia: Illustration of morphologic and immunophenotypic challenges of an emerging phenomenon. Leuk Lymphoma. 2021 12; 62(13):3296-3299.
Score: 0.050
-
Immunophenotypic characterization of reactive and neoplastic plasmacytoid dendritic cells permits establishment of a 10-color flow cytometric panel for initial workup and residual disease evaluation of blastic plasmacytoid dendritic cell neoplasm. Haematologica. 2021 04 01; 106(4):1047-1055.
Score: 0.049
-
The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival. Am J Hematol. 2020 02; 95(2):144-150.
Score: 0.044
-
Early T precursor acute lymphoblastic leukaemia/lymphoma shows differential immunophenotypic characteristics including frequent CD33 expression and in vitro response to targeted CD33 therapy. Br J Haematol. 2019 08; 186(4):538-548.
Score: 0.043
-
Patient with mixed-phenotype acute leukemia with CBFB rearrangement. Leuk Lymphoma. 2019 11; 60(11):2829-2831.
Score: 0.043
-
Early detection of transformation to BPDCN in a patient with MDS. Exp Hematol Oncol. 2018; 7:26.
Score: 0.041
-
Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia. Haematologica. 2019 02; 104(2):305-311.
Score: 0.041
-
Chronic lymphoproliferative disorder of NK-cells: A single-institution review with emphasis on relative utility of multimodality diagnostic tools. Eur J Haematol. 2018 May; 100(5):444-454.
Score: 0.040
-
Mixed phenotype acute leukemia contains heterogeneous genetic mutations by next-generation sequencing. Oncotarget. 2018 Feb 02; 9(9):8441-8449.
Score: 0.039
-
Herpes simplex infection simulating Richter transformation: a series of four cases and review of the literature. Histopathology. 2017 Apr; 70(5):821-831.
Score: 0.037
-
Durable remission with rituximab in a patient with an unusual variant of Castleman's disease with myelofibrosis-TAFRO syndrome. Am J Hematol. 2015 Nov; 90(11):1091-2.
Score: 0.032